Literature DB >> 29540472

Prevalence of Pathogenic Gene Mutations and Prognosis Do Not Differ in Isolated Left Ventricular Dysfunction Compared With Dilated Cardiomyopathy.

Mark R Hazebroek1, Ingrid Krapels2, Job Verdonschot2, Arthur van den Wijngaard2, Els Vanhoutte2, Marije Hoos2, Luc Snijders2, Lieke van Montfort2, Maryvonne Witjens2, Robert Dennert2, Harry J G M Crijns2, Hans-Peter Brunner-La Rocca2, Han G Brunner2, Stephane Heymans2.   

Abstract

BACKGROUND: Genetic evaluation is recommended in patients with unexplained dilated cardiomyopathy (DCM), but its diagnostic yield and prognostic relevance in unexplained isolated left ventricular dysfunction (LVdys) is unknown. METHODS AND
RESULTS: A total of 127 LVdys and 262 DCM patients underwent genetic screening. Long-term outcome consisted of a combined end point of life-threatening arrhythmia, heart transplantation, and death. At baseline, LVdys patients were younger and had less frequently New York Heart Association class ≥3 when compared with DCM (55±13 versus 58±12; P=0.019 and 21% versus 36%; P=0.003, respectively). The prevalence of familial disease and pathogenic mutations was similar in LVdys and DCM (45% versus 40%; P=0.37 and 19% versus 17%; P=0.61, respectively). After a follow-up of 56 (31-82) months, outcome did not differ in LVdys compared with DCM patients (hazard ratio, 0.83; 95% confidence interval, 0.47-1.45; P=0.51). Overall, outcome was less favorable in patients with a genetic mutation or familial disease when compared with those without (hazard ratio, 2.7; 95% confidence interval, 1.07-7.7; P=0.048 and hazard ratio, 2.2; 95% confidence interval, 1.2-4.2; P=0.013, respectively). Thus, the diagnostic yield of genetic testing in LVdys and DCM is similarly high. The presence of a gene mutation or familial predisposition results in an equally worse prognosis.
CONCLUSIONS: Genetic evaluation is advised in LVdys patients and should not merely be restricted to DCM.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  genetic testing; heart transplantation; mutation; prevalence; prognosis

Mesh:

Year:  2018        PMID: 29540472     DOI: 10.1161/CIRCHEARTFAILURE.117.004682

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  6 in total

Review 1.  Risk-Based Approach for the Prediction and Prevention of Heart Failure.

Authors:  Arjun Sinha; Deepak K Gupta; Clyde W Yancy; Sanjiv J Shah; Laura J Rasmussen-Torvik; Elizabeth M McNally; Philip Greenland; Donald M Lloyd-Jones; Sadiya S Khan
Journal:  Circ Heart Fail       Date:  2021-02-04       Impact factor: 8.790

Review 2.  Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know.

Authors:  Upasana Tayal; James S Ware; Neal K Lakdawala; Stephane Heymans; Sanjay K Prasad
Journal:  Eur Heart J       Date:  2021-06-21       Impact factor: 35.855

3.  Establishment of a Dedicated Inherited Cardiomyopathy Clinic: From Challenges to Improved Patients' Outcome.

Authors:  Emily Smith; Paul D Thompson; Carolyn Burke-Martindale; Adaya Weissler-Snir
Journal:  J Am Heart Assoc       Date:  2022-04-26       Impact factor: 6.106

4.  Novel Missense CNTNAP2 Variant Identified in Two Consanguineous Pakistani Families With Developmental Delay, Epilepsy, Intellectual Disability, and Aggressive Behavior.

Authors:  Noor Badshah; Kari A Mattison; Sohail Ahmad; Pankaj Chopra; H Richard Johnston; Shakoor Ahmad; Sher Hayat Khan; Muhammad Tahir Sarwar; David J Cutler; Micheal Taylor; Gayatri Vadlamani; Michael E Zwick; Andrew Escayg
Journal:  Front Neurol       Date:  2022-07-14       Impact factor: 4.086

Review 5.  Einthoven dissertation prizes 2017.

Authors:  J J Piek
Journal:  Neth Heart J       Date:  2018-09       Impact factor: 2.380

Review 6.  Clinical Implications of the Genetic Architecture of Dilated Cardiomyopathy.

Authors:  Lisa D Wilsbacher
Journal:  Curr Cardiol Rep       Date:  2020-10-10       Impact factor: 2.931

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.